T1	DISO 103 125	insuficiencia cardíaca
#1	AnnotatorNotes T1	C0018801; Heart failure; Disease or Syndrome
T2	PROC 148 217	Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos
T3	PROC 223 259	evaluar la seguridad y tolerabilidad
T4	DISO 295 317	insuficiencia cardíaca
#2	AnnotatorNotes T4	C0018801; Heart failure; Disease or Syndrome
T5	CHEM 79 85	LCZ696
#3	AnnotatorNotes T5	C2933615; LCZ 696; Organic Chemical
T6	PROC 344 364	pautas de titulación
T7	CHEM 271 277	LCZ696
#4	AnnotatorNotes T7	C2933615; LCZ 696; Organic Chemical
T8	DISO 388 418	Insuficiencia cardíaca crónica
#5	AnnotatorNotes T8	C0264716; Chronic heart failure; Disease or Syndrome
T9	PROC 466 477	Diagnóstico
#6	AnnotatorNotes T9	C0011900; Diagnosis; Diagnostic Procedure
T10	DISO 481 484	ICC
#7	AnnotatorNotes T10	C0018802; Congestive heart failure; Disease or Syndrome
T11	PROC 624 633	protocolo
#8	AnnotatorNotes T11	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T12	PROC 660 672	TFG estimada
#9	AnnotatorNotes T12	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T13	CHEM 694 701	Potasio
#10	AnnotatorNotes T13	C0032821; potassium; Biologically Active Substance · Element, Ion, or Isotope · Pharmacologic Substance
T14	ANAT 702 708	sérico
#11	AnnotatorNotes T14	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T15	DISO 723 746	Hipotensión sintomática
#12	AnnotatorNotes T15	C0863113; Hypotension symptomatic; Pathologic Function
T16	CHEM 584 596	β bloqueante
#13	AnnotatorNotes T16	C0001645; Adrenergic beta-Antagonists; Pharmacologic Substance
T17	PROC 514 518	FEVI
#14	AnnotatorNotes T17	C2114363; left ventricular ejection fraction assessment; Therapeutic or Preventive Procedure
T18	CHEM 863 867	IECA
#15	AnnotatorNotes T18	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T19	PROC 908 917	protocolo
#16	AnnotatorNotes T19	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T20	PROC 71 78	titular
#17	AnnotatorNotes T20	C4761127; Drug titration; Therapeutic or Preventive Procedure
T21	ANAT 117 125	cardíaca
#18	AnnotatorNotes T21	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T22	ANAT 309 317	cardíaca
#19	AnnotatorNotes T22	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T23	ANAT 402 410	cardíaca
#20	AnnotatorNotes T23	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T24	PROC 568 576	tratados
#21	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 694 708	Potasio sérico
#22	AnnotatorNotes T25	C0302353; Serum potassium measurement; Laboratory Procedure
T26	PROC 751 754	PAS
#23	AnnotatorNotes T26	C1306620; Systolic blood pressure measurement; Diagnostic Procedure
T27	PROC 768 771	PAS
#24	AnnotatorNotes T27	C1306620; Systolic blood pressure measurement; Diagnostic Procedure
T28	DISO 808 820	intolerancia
#25	AnnotatorNotes T28	C0277585; Intolerance to drug; Pathologic Function
T29	CHEM 870 875	ARAII
#26	AnnotatorNotes T29	C0521942; Angiotensin II receptor antagonist; Pharmacologic Substance
T30	Date 13 17	2013
T31	LIVB 89 98	pacientes
#27	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	LIVB 281 290	pacientes
#28	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T33	Duration 411 418	crónica
#29	AnnotatorNotes T33	C0205191; chronic; Temporal Concept
T34	Age 447 454	18 años
T35	PROC 506 510	NYHA
#30	AnnotatorNotes T35	C4706236; Assessment using New York Heart Association Classification; Health Care Activity
T36	LIVB 548 557	pacientes
#31	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
A1	Status T28 History_of
#32	AnnotatorNotes T2	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C2826345; Parallel Study; Research Activity 
#33	AnnotatorNotes T3	C3274448; Tolerability Study; Research Activity + C1705187; Safety Study; Research Activity
R1	Used_for Arg1:T5 Arg2:T20	
R2	Experiences Arg1:T31 Arg2:T20	
R3	Experiences Arg1:T31 Arg2:T1	
R4	Location_of Arg1:T21 Arg2:T1	
R5	Experiences Arg1:T32 Arg2:T7	
R6	Experiences Arg1:T32 Arg2:T4	
R7	Location_of Arg1:T22 Arg2:T4	
R8	Used_for Arg1:T7 Arg2:T6	
R9	Location_of Arg1:T23 Arg2:T8	
R10	Has_Duration_or_Interval Arg1:T8 Arg2:T33	
T37	Result_or_Value 488 499	clase II-IV
R11	Has_Result_or_Value Arg1:T35 Arg2:T37	
T38	Result_or_Value 519 524	≤ 35%
R13	Has_Result_or_Value Arg1:T17 Arg2:T38	
T39	PROC 531 540	selección
#34	AnnotatorNotes T39	C0242802; Patient Selection; Research Activity
R14	Overlap Arg1:T17 Arg2:T39	
R15	Experiences Arg1:T36 Arg2:T24	
R16	Used_for Arg1:T16 Arg2:T24	
T40	Result_or_Value 673 692	< 30 ml/min/1,73 m2
R17	Has_Result_or_Value Arg1:T12 Arg2:T40	
R18	Location_of Arg1:T14 Arg2:T25	
T41	Result_or_Value 709 721	> 5,2 mmol/l
R19	Has_Result_or_Value Arg1:T25 Arg2:T41	
T42	Result_or_Value 755 765	< 100 mmHg
R20	Has_Result_or_Value Arg1:T26 Arg2:T42	
T43	Result_or_Value 772 782	> 180 mmHg
R21	Has_Result_or_Value Arg1:T27 Arg2:T43	
R24	Causes Arg1:T18 Arg2:T28	
R25	Causes Arg1:T29 Arg2:T28	
T44	CONC 827 846	dosis de referencia
R26	Used_for Arg1:T44 Arg2:T18	
R27	Used_for Arg1:T44 Arg2:T29	
A2	Experiencer T31 Patient
A3	Experiencer T32 Patient
A4	Experiencer T36 Patient
